Opthea Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Fred Guerard
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 24.9% |
| CEO tenure | 1.2yrs |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 1.2yrs |
Recent management updates
Recent updates
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?
Jul 21
Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation
Mar 24We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely
Dec 09This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate
Oct 12Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation
Aug 24We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth
Mar 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | US$1m | US$373k | -US$220m |
Compensation vs Market: Fred's total compensation ($USD1.50M) is above average for companies of similar size in the Australian market ($USD888.46K).
Compensation vs Earnings: Insufficient data to compare Fred's compensation with company performance.
CEO
Fred Guerard (52 yo)
1.2yrs
Tenure
US$1,496,440
Compensation
Dr. Frederic Guerard, also known as Fred, Pharm. D., M.S., is Chief Executive Officer of Opthea Limited from October 27, 2023. He has been Independent Director at LENZ Therapeutics, Inc. since September 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.2yrs | US$1.50m | no data | |
| Founder & Chief Innovation Officer | no data | US$1.36m | 0.016% A$ 134.7k | |
| VP of Finance & Company Secretary | 3.5yrs | US$466.17k | 0% A$ 0 | |
| Chief Financial Officer | less than a year | no data | no data | |
| VP of Strategy & Corporate Development | no data | no data | no data | |
| Vice President Marketing | less than a year | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data | |
| Chief Medical Advisor & Chairman of Medical Advisory Board | less than a year | no data | no data | |
| VP Global Clinical Operations | less than a year | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
0.5yrs
Average Tenure
52yo
Average Age
Experienced Management: OPT's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Medical Advisor & Chairman of Medical Advisory Board | less than a year | no data | no data | |
| Chairperson | 4.2yrs | US$309.43k | 0.0051% A$ 43.5k | |
| Independence Non-Executive Director | 2.7yrs | US$135.81k | no data | |
| Independent Non-Executive Director | 3.5yrs | US$170.25k | no data | |
| Member of Medical Advisory Board | less than a year | no data | no data | |
| Independent Non-Executive Director | 4.4yrs | US$790.52k | 0.15% A$ 1.3m | |
| Independent Non-Executive Director | less than a year | US$16.72k | no data | |
| Non-Executive Director | 1.5yrs | US$103.72k | no data | |
| Independent Non-Executive Director | 2.7yrs | US$130.26k | no data | |
| Member of Medical Advisory Board | less than a year | no data | no data | |
| Member of Medical Advisory Board | less than a year | no data | no data | |
| Member of Medical Advisory Board | less than a year | no data | no data |
1.2yrs
Average Tenure
62yo
Average Age
Experienced Board: OPT's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Opthea Limited is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |
| Yigal Nochomovitz | Citigroup Inc |